209 related articles for article (PubMed ID: 37441876)
1. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212).
Heinrich K; Karthaus M; Fruehauf S; Graeven U; Mueller L; König AO; von Weikersthal LF; Caca K; Kretzschmar A; Goekkurt E; Haas S; Alig AHS; Kurreck A; Stahler A; Held S; Sommerhäuser G; Heinemann V; Stintzing S; Trarbach T; Modest DP
ESMO Open; 2023 Aug; 8(4):101568. PubMed ID: 37441876
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
[TBL] [Abstract][Full Text] [Related]
3. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
4. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Sommerhäuser G; Kurreck A; Beck A; Fehrenbach U; Karthaus M; Fruehauf S; Graeven U; Mueller L; Koenig AO; V Weikersthal LF; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper S; Stintzing S; Trarbach T; Modest DP
Eur J Cancer; 2023 Jan; 178():37-48. PubMed ID: 36399909
[TBL] [Abstract][Full Text] [Related]
5. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract][Full Text] [Related]
6. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Ballhausen A; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; von Weikersthal LF; Sommerhäuser G; Alig AHS; Goekkurt E; Meyer-Knees JW; Kurreck A; Stahler A; Held S; Kasper S; Heinrich K; Heinemann V; Stintzing S; Trarbach T; Modest DP
Eur J Cancer; 2023 Sep; 190():112955. PubMed ID: 37454537
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Sommerhäuser G; Karthaus M; Kurreck A; Ballhausen A; Meyer-Knees JW; Fruehauf S; Graeven U; Mueller L; Koenig AO; Weikersthal LFV; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper-Virchow S; Stintzing S; Trarbach T; Modest DP
Int J Cancer; 2024 Mar; 154(5):863-872. PubMed ID: 37840339
[TBL] [Abstract][Full Text] [Related]
9. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
10. Negative Hyperselection of Patients With
Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
12. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
13. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Tian Y; Xu F; Sidhu R
Ann Oncol; 2014 Jul; 25(7):1346-1355. PubMed ID: 24718886
[TBL] [Abstract][Full Text] [Related]
14. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
[TBL] [Abstract][Full Text] [Related]
15. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study.
Raimondi A; Fucà G; Leone AG; Lonardi S; Antoniotti C; Smiroldo V; Amatu A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Berenato R; Ratti M; Corallo S; Morano F; Di Bartolomeo M; Di Maio M; Pietrantonio F
ESMO Open; 2021 Oct; 6(5):100246. PubMed ID: 34416469
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
17. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S; Rasola C; Lobefaro R; Rossini D; Formica V; Scartozzi M; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Pella N; Bergamo F; Raimondi A; Arnoldi E; Antonuzzo L; Granetto C; Zustovich F; Ronzoni M; Leo S; Morano F; Loupakis F; Buggin F; Zagonel V; Fassan M; Cremolini C; Boni L; Pietrantonio F;
J Clin Oncol; 2023 Dec; 41(34):5263-5273. PubMed ID: 37535876
[TBL] [Abstract][Full Text] [Related]
18. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Raimondi A; Nichetti F; Stahler A; Wasan HS; Aranda E; Randon G; Kurreck A; Meade AM; Díaz-Rubio E; Niger M; Stintzing S; Palermo F; Trarbach T; Prisciandaro M; Sommerhäuser G; Fisher D; Morano F; Pietrantonio F; Modest DP
Eur J Cancer; 2023 Sep; 190():112945. PubMed ID: 37441940
[TBL] [Abstract][Full Text] [Related]
19. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP
BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060
[TBL] [Abstract][Full Text] [Related]
20. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tian Y; Sidhu R
Ann Oncol; 2014 Jan; 25(1):107-16. PubMed ID: 24356622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
